Amoolya Gowda

494 total citations · 1 hit paper
13 papers, 322 citations indexed

About

Amoolya Gowda is a scholar working on Endocrinology, Diabetes and Metabolism, Genetics and Surgery. According to data from OpenAlex, Amoolya Gowda has authored 13 papers receiving a total of 322 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Endocrinology, Diabetes and Metabolism, 5 papers in Genetics and 2 papers in Surgery. Recurrent topics in Amoolya Gowda's work include Diabetes Management and Research (10 papers), Diabetes Treatment and Management (10 papers) and Diabetes and associated disorders (4 papers). Amoolya Gowda is often cited by papers focused on Diabetes Management and Research (10 papers), Diabetes Treatment and Management (10 papers) and Diabetes and associated disorders (4 papers). Amoolya Gowda collaborates with scholars based in Denmark, United States and Canada. Amoolya Gowda's co-authors include Ildiko Lingvay, Julio Rosenstock, Harpreet S. Bajaj, Roberto Trevisan, Melanie J. Davies, Bo Liang, Tomoyuki Nishida, Stephen C. Bain, Ofri Mosenzon and Esteban Jódar and has published in prestigious journals such as New England Journal of Medicine, Annals of Internal Medicine and Diabetes Care.

In The Last Decade

Amoolya Gowda

12 papers receiving 314 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin

2023 91 citations Julio Rosenstock, Stephen C. Bain et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Amoolya Gowda

Since Specialization

Citations

This map shows the geographic impact of Amoolya Gowda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amoolya Gowda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amoolya Gowda more than expected).

Fields of papers citing papers by Amoolya Gowda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amoolya Gowda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amoolya Gowda. The network helps show where Amoolya Gowda may publish in the future.

Co-authorship network of co-authors of Amoolya Gowda

This figure shows the co-authorship network connecting the top 25 collaborators of Amoolya Gowda. A scholar is included among the top collaborators of Amoolya Gowda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amoolya Gowda. Amoolya Gowda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

#	Work	Indexed citations
1	Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial 2025 ·The Lancet Diabetes & Endocrinology ·Liana K. Billings, Francesco Andreozzi, Marie Frederiksen, Pierre Gourdy, Amoolya Gowda, Linong Ji, (unknown), Ryo Suzuki, (unknown), André Gustavo Daher Vianna	5
2	Once-Weekly Insulin Icodec With Dosing Guide App Versus Once-Daily Basal Insulin Analogues in Insulin-Naive Type 2 Diabetes (ONWARDS 5) 2023 ·Annals of Internal Medicine ·Harpreet S. Bajaj, Jens Aberle, Melanie J. Davies, Anders Meller Donatsky, Marie Frederiksen, Di̇lek Gogas Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce W. Bode	57
3	Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin breakdown → 2023 ·New England Journal of Medicine ·Julio Rosenstock, Stephen C. Bain, Amoolya Gowda, Esteban Jódar, Bo Liang, Ildiko Lingvay, Tomoyuki Nishida, Roberto Trevisan, Ofri Mosenzon	91
4	803-P: Superior Glycemic Control with Once-Weekly Insulin Icodec with a Dosing Guide App vs. Once-Daily (OD) Basal Insulin Analogs in Insulin-Naïve T2D—ONWARDS 5 2023 ·Diabetes ·Harpreet S. Bajaj, Jens Aberle, Melanie J. Davies, Anders Meller Donatsky, Marie Frederiksen, Di̇lek Gogas Yavuz, Amoolya Gowda, (unknown), Bruce W. Bode	1
5	179-OR: Improved A1C and TIR with Once-Weekly Insulin Icodec vs. Insulin Glargine U100 in Insulin-Naïve T2D—ONWARDS 1 2023 ·Diabetes ·(unknown), Stephen C. Bain, Amoolya Gowda, (unknown), Esteban Jódar, (unknown), (unknown), Roberto Trevisan, (unknown)	0
6	Rationale and design of the phase 3a development programme ( ONWARDS 1–6 trials) investigating once‐weekly insulin icodec in diabetes 2022 ·Diabetes Obesity and Metabolism ·Athena Philis‐Tsimikas, Harpreet S. Bajaj, Kamilla Begtrup, (unknown), Amoolya Gowda, Ildiko Lingvay, Chantal Mathieu, David Russell‐Jones, Julio Rosenstock	51
7	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial 2021 ·Diabetes Care ·Harpreet S. Bajaj, Richard M. Bergenstal, (unknown), Melanie J. Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter Senior, Robert Silver, Roberto Trevisan, Julio Rosenstock	77
8	Duration of type 2 diabetes does not appear to moderate hypoglycaemia rate with insulin degludec versus insulin glargine U100 2021 ·Diabetes Obesity and Metabolism ·Anastasia‐Stefania Alexopoulos, Andreas Andersen, Anders Meller Donatsky, Amoolya Gowda, John B. Buse	2
9	Hemoglobin glycation index, calculated from a single fasting glucose value, as a prediction tool for severe hypoglycemia and major adverse cardiovascular events in DEVOTE 2021 ·BMJ Open Diabetes Research & Care ·Klara R. Klein, Edward Franek, Steven P. Marso, Thomas R. Pieber, Richard E. Pratley, Amoolya Gowda, Kajsa Kvist, John B. Buse	28
10	731-P: CGM-Based Measurements for Once-Weekly Insulin Icodec vs. Once-Daily Insulin Glargine U100 in Insulin-Treated Patients with T2D: A Post-hoc Analysis 2021 ·Diabetes ·Harpreet S. Bajaj, (unknown), Amoolya Gowda, (unknown), Peter Senior, Richard M. Bergenstal	1
11	The wound healing property of ethanolic extract of <i>Michelia champaca</i> flowers in diabetic rats 2014 ·International Journal of Basic & Clinical Pharmacology ·Amoolya Gowda, (unknown), (unknown), Smita Shenoy, Krishnananda Prabhu, (unknown), (unknown)	1
12	Wound healing property of topical application of ethanolic extract of Michelia champaca flowers in diabetic rats 2013 ·(unknown), Krishnananda Prabhu, (unknown), Smita Shenoy, Amoolya Gowda, (unknown)	7
13	A Retrospective Study of the Drug Prescribing Pattern in Crohn’s Disease (CD)in a Tertiary Care Hospital 2013 ·International Journal of Pharmaceutical Sciences Review and Research ·(unknown), (unknown), (unknown), Ganesh Bhat, Smita Shenoy, Amoolya Gowda	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact